

Title (en)

MEDICAMENT FOR THE TREATMENT OF DISEASES REQUIRING INHIBITION OR A REDUCTION IN THE ACTIVITY OF PH VALUE-REGULATING BICARBONATE TRANSPORTER PROTEINS

Title (de)

ARZNEIMITTEL ZUR BEHANDLUNG VON EINE INHIBITION ODER AKTIVITÄTSVERMINDERUNG VON PH-WERT-REGULIERENDEN BIKARBONAT-TRANSPORTER-PROTEINEN ERFORDERNDEN ERKRANKUNGEN

Title (fr)

MEDICAMENT POUR TRAITER DES AFFECTIONS IMPLIQUANT UNE INHIBITION OU UNE BAISSSE D'ACTIVITE DE PROTEINES TRANSPORTEUSES DE BICARBONATE REGULANT LE PH

Publication

EP 1517688 A2 20050330 (DE)

Application

EP 03760622 A 20030616

Priority

- EP 03760622 A 20030616
- EP 0306319 W 20030616
- EP 02013387 A 20020619

Abstract (en)

[origin: WO2004000312A2] Disclosed is the use of selective imidazoline receptor agonists, particularly moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847, and BU-98008, and the physiologically acceptable salts thereof, for the production of pharmaceutical preparations used for treating and/or preventing functional disturbances and/or diseases in larger mammals or humans, which require inhibition or a reduction in the activity of proteins that regulate the intracellular pH value and belong to the superfamily of bicarbonate transporters, particularly diseases which affect the bones as a result of an undesired bone resorption level, especially osteoporosis, diseases of the gastrointestinal tract, especially gastric ulcers, and neural and/or neuropsychiatric diseases that are related to a pathologically modified, preferably an increased, neural activity, preferably depression, Alzheimer's, eating disorders, and schizophrenia.

IPC 1-7

A61K 31/421; **A61K 31/506**; **A61K 31/47**; **A61K 31/496**; **A61P 19/00**; **A61P 1/00**; **A61P 25/00**

IPC 8 full level

A61K 31/4178 (2006.01); **A61K 31/421** (2006.01); **A61K 31/47** (2006.01); **A61K 31/496** (2006.01); **A61K 31/506** (2006.01); **A61P 1/00** (2006.01); **A61P 19/00** (2006.01); **A61P 25/00** (2006.01)

CPC (source: EP US)

A61K 31/4178 (2013.01 - EP US); **A61K 31/421** (2013.01 - EP US); **A61K 31/47** (2013.01 - EP US); **A61K 31/496** (2013.01 - EP US); **A61K 31/506** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP)

Citation (search report)

See references of WO 2004000312A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004000312 A2 20031231; **WO 2004000312 A3 20040219**; AU 2003257418 A1 20040106; CA 2487541 A1 20031231; EP 1517688 A2 20050330; PL 372695 A1 20050725; US 2005165080 A1 20050728; US 7309706 B2 20071218

DOCDB simple family (application)

EP 0306319 W 20030616; AU 2003257418 A 20030616; CA 2487541 A 20030616; EP 03760622 A 20030616; PL 37269503 A 20030616; US 1332604 A 20041217